NCT07864025 Identification of Lesion Characteristics in Coronary Plaques Using Multimodality Intravascular Imaging and Novel Photon-counting CT in Stable Angina
| NCT ID | NCT07864025 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Queen Mary University of London |
| Condition | Coronary Artery Disease (CAD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 70 participants |
| Start Date | 2026-08-19 |
| Primary Completion | 2029-04-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 70 participants in total. It began in 2026-08-19 with a primary completion date of 2029-04-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Coronary artery disease, caused by the furring up of the heart arteries by atherosclerosis, is a major cause of death in the UK. Despite existing therapies, adverse cardiovascular events remains high, especially in patients who have already had a heart attack, as some of these patients have aggressive atherosclerotic disease. If we could identify these vulnerable patients, then in wider clinical practice in the future we might be able to treat them better with new therapies that can otherwise be expensive or come with a risk of side-effects. Traditionally, the assessment of atherosclerotic disease and the identification of the plaques that will cause heart attacks is performed using invasive imaging - imaging taken by passing a wire into the arteries of the heart that has a camera on its tip. Invasive imaging, however, can be used only in patients with symptoms and has risks. Photon counting (PC) CT is a new CT system that has image quality comparable to invasive imaging and can be used in the community to examine individuals with stable angina symptoms. In this study we aim to compare how well PC-CT detects high-risk plaques compared with invasive imaging and in due course develop a platform that will expedite the analysis of CT images to allow its broad use in the clinical practice.
Eligibility Criteria
Inclusion Criteria: * Able and willing to give informed consent * Between ages 18-79 * Patients with a stable coronary syndrome that had recent PC-CTA showing at least one lesion requiring further evaluation with intravascular imaging or fractional flow reserve and is considered suitable for PCI under IVUS guidance Exclusion Criteria: * Unable to or unwilling to give informed consent * Age \>80 years * Recent acute coronary syndrome within \< 3 months * Renal failure (eGFR \<60ml/min/1.73m²) * History of previous coronary artery bypass surgery * Decompensated heart failure, or left ventricular ejection fraction ≤30% * Previous heart transplantation * Intravenous contrast allergy * Unable to receive treatment with aspirin, heparin, or thienopyridines * Anticipated life expectancy \<1 year * Pregnancy * Patient that requires surgical revascularisation * Extensive coronary artery disease (i.e. multiple chronic total occlusions) or tortuous coronary anatomy that does not allow assessment of the coronary arteries with NIRS-IVUS imaging
Contact & Investigator
Christos V Bourantas, MD PhD
PRINCIPAL INVESTIGATOR
Barts Health NHS Trust and Queen Mary University of London
Frequently Asked Questions
Who can join the NCT07864025 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 79 Years, studying Coronary Artery Disease (CAD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07864025 currently recruiting?
Yes, NCT07864025 is actively recruiting participants. Contact the research team at a.h.a.khan@qmul.ac.uk for enrollment information.
Where is the NCT07864025 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT07864025 clinical trial?
NCT07864025 is sponsored by Queen Mary University of London. The principal investigator is Christos V Bourantas, MD PhD at Barts Health NHS Trust and Queen Mary University of London. The trial plans to enroll 70 participants.